Terms: = Ovarian cancer AND CCNE1, CCNE, 898, ENSG00000105173, P24864 AND Prognosis
25 results:
1. Survival time prediction in patients with high-grade serous ovarian cancer based on
He D; Zhang X; Chang Z; Liu Z; Li B
BMC Cancer; 2024 Mar; 24(1):337. PubMed ID: 38475819
[TBL] [Abstract] [Full Text] [Related]
2. Compartment-specific multiomic profiling identifies SRC and GNAS as candidate drivers of epithelial-to-mesenchymal transition in ovarian carcinosarcoma.
Herrington CS; Oswald AJ; Stillie LJ; Croy I; Churchman M; Hollis RL
Br J Cancer; 2024 Feb; 130(2):327-335. PubMed ID: 38097740
[TBL] [Abstract] [Full Text] [Related]
3. Spatial and temporal intra-tumoral heterogeneity in advanced HGSOC: Implications for surgical and clinical outcomes.
Cunnea P; Curry EW; Christie EL; Nixon K; Kwok CH; Pandey A; Wulandari R; Thol K; Ploski J; Morera-Albert C; McQuaid S; Lozano-Kuehne J; Clark JJ; Krell J; Stronach EA; McNeish IA; Bowtell DDL; Fotopoulou C
Cell Rep Med; 2023 Jun; 4(6):101055. PubMed ID: 37220750
[TBL] [Abstract] [Full Text] [Related]
4. ccne1 is a predictive and immunotherapeutic indicator in various cancers including UCEC: a pan-cancer analysis.
Zheng X; Chen L; Liu W; Zhao S; Yan Y; Zhao J; Tian W; Wang Y
Hereditas; 2023 Mar; 160(1):13. PubMed ID: 36964635
[TBL] [Abstract] [Full Text] [Related]
5. ccne1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An ovarian Tumor Tissue Analysis consortium study.
Kang EY; Weir A; Meagher NS; Farrington K; Nelson GS; Ghatage P; Lee CH; Riggan MJ; Bolithon A; Popovic G; Leung B; Tang K; Lambie N; Millstein J; Alsop J; Anglesio MS; Ataseven B; Barlow E; Beckmann MW; Berger J; Bisinotto C; Bösmüller H; Boros J; Brand AH; Brooks-Wilson A; Brucker SY; Carney ME; Casablanca Y; Cazorla-Jiménez A; Cohen PA; Conrads TP; Cook LS; Coulson P; Courtney-Brooks M; Cramer DW; Crowe P; Cunningham JM; Cybulski C; Darcy KM; El-Bahrawy MA; Elishaev E; Erber R; Farrell R; Fereday S; Fischer A; García MJ; Gayther SA; Gentry-Maharaj A; Gilks CB; ; Grube M; Harnett PR; Harrington SP; Harter P; Hartmann A; Hecht JL; Heikaus S; Hein A; Heitz F; Hendley J; Hernandez BY; Polo SH; Heublein S; Hirasawa A; Høgdall E; Høgdall CK; Horlings HM; Huntsman DG; Huzarski T; Jewell A; Jimenez-Linan M; Jones ME; Kaufmann SH; Kennedy CJ; Khabele D; Kommoss FKF; Kruitwagen RFPM; Lambrechts D; Le ND; Lener M; Lester J; Leung Y; Linder A; Loverix L; Lubiński J; Madan R; Maxwell GL; Modugno F; Neuhausen SL; Olawaiye A; Olbrecht S; Orsulic S; Palacios J; Pearce CL; Pike MC; Quinn CM; Mohan GR; Rodríguez-Antona C; Ruebner M; Ryan A; Salfinger SG; Sasamoto N; Schildkraut JM; Schoemaker MJ; Shah M; Sharma R; Shvetsov YB; Singh N; Sonke GS; Steele L; Stewart CJR; Sundfeldt K; Swerdlow AJ; Talhouk A; Tan A; Taylor SE; Terry KL; Tołoczko A; Traficante N; Van de Vijver KK; van der Aa MA; Van Gorp T; Van Nieuwenhuysen E; van-Wagensveld L; Vergote I; Vierkant RA; Wang C; Wilkens LR; Winham SJ; Wu AH; Benitez J; Berchuck A; Candido Dos Reis FJ; DeFazio A; Fasching PA; Goode EL; Goodman MT; Gronwald J; Karlan BY; Kommoss S; Menon U; Sinn HP; Staebler A; Brenton JD; Bowtell DD; Pharoah PDP; Ramus SJ; Köbel M
Cancer; 2023 Mar; 129(5):697-713. PubMed ID: 36572991
[TBL] [Abstract] [Full Text] [Related]
6. Identification of genes and pathways associated with sex in Non-smoking lung cancer population.
Xu L; Wang L; Cheng M
Gene; 2022 Jul; 831():146566. PubMed ID: 35577039
[TBL] [Abstract] [Full Text] [Related]
7. High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer.
Aziz D; Lee C; Chin V; Fernandez KJ; Phan Z; ; ; Waring P; Caldon CE
J Pathol Clin Res; 2022 Jul; 8(4):355-370. PubMed ID: 35384378
[TBL] [Abstract] [Full Text] [Related]
8. Integrated miRNA-mRNA Expression Profiles Revealing Key Molecules in ovarian cancer Based on Bioinformatics Analysis.
Li C; Hong Z; Ou M; Zhu X; Zhang L; Yang X
Biomed Res Int; 2021; 2021():6673655. PubMed ID: 34734085
[TBL] [Abstract] [Full Text] [Related]
9. Uterine serous carcinoma: key advances and novel treatment approaches.
Ferriss JS; Erickson BK; Shih IM; Fader AN
Int J Gynecol Cancer; 2021 Aug; 31(8):1165-1174. PubMed ID: 34210768
[TBL] [Abstract] [Full Text] [Related]
10.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract] [Full Text] [Related]
11. Prognostic and Theranostic Biomarkers in ovarian Clear Cell Carcinoma.
Wiedemeyer K; Wang L; Kang EY; Liu S; Ou Y; Kelemen LE; Feil L; Anglesio MS; Glaze S; Ghatage P; Nelson GS; Köbel M
Int J Gynecol Pathol; 2022 Mar; 41(2):168-179. PubMed ID: 33770057
[TBL] [Abstract] [Full Text] [Related]
12. Transcriptional analysis of multiple ovarian cancer cohorts reveals prognostic and immunomodulatory consequences of ERV expression.
Natoli M; Gallon J; Lu H; Amgheib A; Pinato DJ; Mauri FA; Marafioti T; Akarca AU; Ullmo I; Ip J; Aboagye EO; Brown R; Karadimitris A; Ghaem-Maghami S
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436485
[TBL] [Abstract] [Full Text] [Related]
13. Combined ccne1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma.
Chan AM; Enwere E; McIntyre JB; Wilson H; Nwaroh C; Wiebe N; Ou Y; Liu S; Wiedemeyer K; Rambau PF; Grevers X; Morris DG; Neri P; Gilks CB; Visser F; Le N; Luo L; Cook LS; Köbel M
J Pathol Clin Res; 2020 Oct; 6(4):252-262. PubMed ID: 32391646
[TBL] [Abstract] [Full Text] [Related]
14. Distinct gene expression profiles associated with clinical outcomes in patients with ovarian clear cell carcinoma and high-grade serous ovarian carcinoma.
Zhou H; Liu Q; Shi X; Liu Y; Cao D; Yang J
J Ovarian Res; 2020 Apr; 13(1):38. PubMed ID: 32295618
[TBL] [Abstract] [Full Text] [Related]
15. Tumour-suppressive microRNA-424-5p directly targets ccne1 as potential prognostic markers in epithelial ovarian cancer.
Liu J; Gu Z; Tang Y; Hao J; Zhang C; Yang X
Cell Cycle; 2018; 17(3):309-318. PubMed ID: 29228869
[TBL] [Abstract] [Full Text] [Related]
16. ccne1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis.
Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL
Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100
[TBL] [Abstract] [Full Text] [Related]
17. Comparison of Clinical Outcomes of
Eoh KJ; Park HS; Park JS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
Cancer Res Treat; 2017 Apr; 49(2):408-415. PubMed ID: 27488874
[TBL] [Abstract] [Full Text] [Related]
18. Cyclin E as a potential therapeutic target in high grade serous ovarian cancer.
Kanska J; Zakhour M; Taylor-Harding B; Karlan BY; Wiedemeyer WR
Gynecol Oncol; 2016 Oct; 143(1):152-158. PubMed ID: 27461360
[TBL] [Abstract] [Full Text] [Related]
19. Genomic Characterization of High-Grade Serous ovarian cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies.
Mittempergher L
Curr Oncol Rep; 2016 Jul; 18(7):44. PubMed ID: 27241520
[TBL] [Abstract] [Full Text] [Related]
20. Immunohistochemical Profiling of Endometrial Serous Carcinoma.
Chen W; Husain A; Nelson GS; Rambau PF; Liu S; Lee CH; Lee S; Duggan MA; Köbel M
Int J Gynecol Pathol; 2017 Mar; 36(2):128-139. PubMed ID: 27167671
[TBL] [Abstract] [Full Text] [Related]
[Next]
